NCT05101551 2026-04-22
PARPAML
Stanford University
Phase 1 Recruiting
Clinical Trials
21 trialsNCT06840886 2026-04-22
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
Phase 1 Recruiting
NCT07099898 2026-04-22
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
GlaxoSmithKline
Phase 3 Recruiting
NCT06828354 2026-04-20
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT06994195 2026-04-20
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06459180 2026-04-17
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07213804 2026-04-17
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT07214779 2026-04-16
MAESTRA 2
Incyte Corporation
Phase 3 Recruiting
NCT06666712 2026-04-15
TPT CED rHGG
Columbia University
Phase 1 Recruiting
NCT06172296 2026-04-14
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT07418749 2026-04-06
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT05521984 2026-04-02
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
Washington University School of Medicine
Phase 1 Recruiting
NCT06930755 2026-03-31
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Nerviano Medical Sciences
Phase 1 Recruiting
NCT06801834 2026-03-19
EVOKE-SCLC-04
Gilead Sciences
Phase 3 Recruiting
NCT07194044 2026-03-16
METTSEO
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT06203210 2026-03-02
IDeate-Lung02
Daiichi Sankyo
Phase 3 Recruiting
NCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
NCT04322318 2026-02-24
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Children's Oncology Group
Phase 2 Recruiting
NCT06647953 2026-02-24
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Children's Oncology Group
Phase 3 Recruiting
NCT05535166 2026-02-12
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT06528496 2026-02-10
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting